Euglycaemic ketoacidosis in a postoperative Whipple patient using canaglifozin

BMJ Case Reports

Volumn 2016, Issue , 2016, Pages

  Wood, Trevor ^a   Pang, Allison J ^a   Hallet, Julie ^b   Greig, Paul ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CANAGLIFLOZIN; CREATININE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; KETONE; LACTIC ACID; LINAGLIPTIN; METFORMIN;

ACUTE KIDNEY FAILURE; AGED; ARTERIAL GAS; ARTICLE; ASIAN; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIABETIC KETOACIDOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EUGLYCEMIC DIABETIC KETOACIDOSIS; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; LABORATORY TEST; MALE; MEDICAL HISTORY; METABOLIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; TACHYCARDIA; TUBERCULOSIS; TUMOR VOLUME; URINE VOLUME;

EID: 84990245351     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2016-216607     Document Type: Article

References (10)

1. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015;38:1638-42.
2. Food and Drug Administration. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood: Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm.
3. European Medicines Agency. Review of diabetes medicines called SGLT2 inhibitors started: risk of diabetic ketoacidosis to be examined. http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/SGLT2-inhibitors-20/Procedure-started/WC500187926.pdf.
4. Kalra S. Sodium Glucose Co-Transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther 2014;5:355-66.
5. Kitabchi AE, Umpierrez GE, Miles JM, et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009;32:1335-43.
6. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1687-93.
7. Thawabi M, Studyvin S. Euglycemic diabetic ketoacidosis, a misleading presentation of diabetic ketoacidosis. N Am J Med Sci 2015;7:291-4.
8. Erondu N, Desai M, Ways K, et al. Diabetic ketoacidosis and related events in the Canagliflozin Type 2 diabetes clinical program. Diabetes Care 2015;38:1680-6.
9. The Endocrine Society. A case report of ketoacidosis associated with canagliflozin (Invokana). https://endo.confex.com/endo/2015endo/webprogram/Paper21461.html.
10. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015;75:33-59.